The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...